StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) bonds

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)

Close on Nov 18, 2026Market cap $99.30MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Outlook Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Sep 30, 2022

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Outlook Therapeutics's 10-Q for the period ended Jun 30, 2026

IssueCouponAmount issuedCarrying value
March 2025 Note
Convertible at $2 a share
Floating + 3.00%$33.10M–
March 2026 NoteFloating + 3.00%$18.36M–
Unsecured convertible promissory notes–$31.82M–
Unsecured promissory notes-aggregate––$36.66M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

See a number that looks wrong?